Filing Flows

Filing Flows › Companies › Yarrow Bioscience › Cash flow

Yarrow Bioscience cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.0M in Q2 2026 · −$16.9M over twelve months

Operating cash flow−$2.0M
Free cash flow−$2.0M

Analysis

In Q2 2026, Yarrow Bioscience generated −$2.0M of operating cash flow. That is $8.8M more than in Q2 2025 (−$10.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$16.9M; the largest uses were operating cash flow ($16.9M), other financing ($51K); besides operations, cash came from other investing ($17.9M); the cash balance rose by $878K.

Operating cash flow was −$2.0M against net income of −$3.0M. The largest differences: stock-based pay +$436K, payables +$316K, prepaid and other assets +$260K.

Free cash flow

Yarrow Bioscience: free cash flow by quarterYarrow Bioscience: free cash flow by quarter−$8.0MQ1 2024−$8.5MQ2 2024−$8.5MQ3 2024−$9.0MQ4 2024−$11.5MQ1 2025−$10.8MQ2 2025−$4.1MQ1 2026−$2.0MQ2 2026
Operating cash flow less capital spending.
Yarrow Bioscience: operating cash flow against capital spendingYarrow Bioscience: operating cash flow against capital spendingOperating cash flowCapital spending−$8.0M$0Q1 2024−$8.5M$0Q2 2024−$8.5M$0Q3 2024−$9.0M$0Q4 2024−$11.5M$0Q1 2025−$10.8M$0Q2 2025−$4.1M$0Q1 2026−$2.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.0M, Capital spending $0.

Capital allocation, year by year

Yarrow Bioscience: where the cash came from (up) and went (down), by fiscal yearYarrow Bioscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$56.4MFY2021: Net borrowing −$36.4MFY2021: Shares issued $76.5MFY2021: Asset sales $100K$76.6MFY2021FY2022: Operating cash flow −$29.2MFY2022: Shares issued $1.7MFY2022: Asset sales $16.0M$17.6MFY2022FY2023: Operating cash flow −$25.3MFY2023: Asset sales $5.0M$5.0MFY2023FY2024: Operating cash flow −$34.0MFY2024: Capital spending −$117KFY2024FY2025: Operating cash flow −$33.1MFY2025
Over these 5 years operating cash flow totalled −$178M; the largest uses were operating cash flow ($178M) and net borrowing ($36.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$29.0M
Debtnone
Net cash$29.0M
Cash runway21 months

Yarrow Bioscience is burning cash: its operations consume cash, a free cash flow of −$16.9M a year at the current rate against $29.0M of cash and investments: a runway of about 21 months before any new financing.

Where the cash came from and went

Yarrow Bioscience: sources (+) and uses (−) of cash, Q2 2026Yarrow Bioscience: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.0MCash drawn (+) / kept (−)$1.7MOther investing$300KOther financing−$14K
Yarrow Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Yarrow Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$17.9MOperating cash flow−$16.9MCash drawn (+) / kept (−)−$878KOther financing−$51K

From profit to cash

Yarrow Bioscience: net income to operating cash flow, Q2 2026Yarrow Bioscience: net income to operating cash flow, Q2 2026Net income−$3.0MDepreciation & amortization$6KStock-based pay$436KPayables$316KPrepaid and other assets$260KOperating cash flow−$2.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.0M$1.7M−$2.0M
Q1 2026−$4.1M−$604K−$4.1M
Q2 2025−$10.8M$6.2M−$10.8M
Q1 2025−$11.5M−$8.3M−$11.5M
Q4 2024−$9.0M−$3.6M−$9.0M
Q3 2024−$8.5M$13.3M−$8.5M
Q2 2024−$8.5M−$10.5M−$8.5M
Q1 2024−$8.0M$11.6M−$8.0M

Yarrow Bioscience: income statement and cash flow

Yarrow Bioscience, Q2 2026: revenue $97K (+41% year over year). The chart follows the revenue to costs, profit and cash.

Yarrow Bioscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.